Seeking Alpha


Send Message
View as an RSS Feed
View jstratt's Comments BY TICKER:
Latest  |  Highest rated
  • More Carnage In Junior Biotechs: General Comments With Focus On Opko And Acceleron [View article]
    I will follow OPK a little closer based on the interesting details outlined in the article.

    It is always interesting how articles like "Step away from Biotech" come after huge drops. I think it was the same guy telling us to buy at the peak.

    Looking forward to earnings in a few weeks for some of my favorite large cap biotechs.
    Oct 1, 2015. 09:03 AM | Likes Like |Link to Comment
  • Use The Biotech Selloff To Buy Gilead [View article]
    As a follow up to Carl Icahn who has stated that earnings are manipulated. As I applied that thought pattern to GILD it did not fit.

    The cash generation is just amazing!
    Sep 30, 2015. 08:13 PM | 2 Likes Like |Link to Comment
  • Regeneron and Sanofi's Praluent cleared in the EU [View news story]
    The downdraft in both REGN and AMGN suggests to me that PCSK9 prospects got downgraded but I havent seen any news to that effect. My guess is pricing related.

    I will just say that PCSK9 even in the narrow group of those afflicted with a genetic disorder will save the lives of several million people. So I tend to think a more rapid uptake to a base level is likely.

    If I had to guess pricing will end up at 60% of list or $8500 and at least a million patients within the next year.
    Sep 30, 2015. 09:37 AM | Likes Like |Link to Comment
  • Use The Biotech Selloff To Buy Gilead [View article]

    I hope DTM estimates are as accurate as recent history suggests!

    In general it is a time of waiting with my GILD holdings. I remain optimistic that GILD will take actions which cause the company to be more fairly valued. When that will happen is a different question.

    So I ask why is GILD not worth 13 PE X $12 =$156? I really thought that would happen by now. When will the future of GILD look like it is sufficiently reasonable to value it as a long term ongoing enterprise, I dont know. Yet I would suggest that historically it is after many believers have given up.

    It is taking longer to get fair value for my GILD shares than I thought but I am far from unhappy and reluctant to chip down my estimated value to $112. GILD will take action to make the pipeline more visible and that will like be what drives the shares higher.
    Sep 30, 2015. 09:19 AM | 2 Likes Like |Link to Comment
  • Biotech Could Just Be The Beginning... [View article]
    I think the author has read too many novels.

    Lets suggest that GILD or AMGN which are profitable and have dividends are considered for investment. Taking GILD it already generates about 22 bil in FCF giving a 16% FCF yield and an 8 PE on 2015 estimates.

    Taking AMGN a 13.56 PE on 2015 EPS estimates and a 2.39% dividend yield is excellent. Especially for a company with 10% growth from already approved drugs.

    My point is labeling these companies as biotech instead of pharma and suggesting that a GILD could drop by 50% to a 4 PE or AMGN to a 6.75 PE is illogical.

    Then for the smaller research biotechs, yes they can fall but they were high risk to those who bought them. Those that come up with research proving a treatment or cure for Cancer, Hepatitis B, Alzheimers, Cholesterol caused Heart disease, NASH, Crohns, IBD or many other diseases will have significant value.
    Sep 28, 2015. 09:59 PM | 7 Likes Like |Link to Comment
  • CVS Health Will Hold Onto Its No. 1 Position [View article]
    I bought some CVS today as it is superbly managed.

    The value of CVS is in the strategic acquisitions into PBM, institutional pharmacy etc. rather than the positioning of Oreo cookies or the elimination of tobacco.

    One has to like the growth of CVS in a growing health care industry. Now with CVS we are starting to find a time to acquire that growth for a good value.
    Sep 28, 2015. 04:31 PM | 1 Like Like |Link to Comment
  • Pair of upgrades for Citigroup [View news story]
    C with its great international lending prowess is once again under $5 per share when accounting for the reverse stock split.
    Sep 28, 2015. 02:04 PM | Likes Like |Link to Comment
  • Biotechs Battered: Comments On All 6 Major Biotech Stocks [View article]

    Curious to hear your thoughts on GILDs Pan Genotype results recently published as well?
    Sep 28, 2015. 01:08 PM | Likes Like |Link to Comment
  • Biotechs Battered: Comments On All 6 Major Biotech Stocks [View article]
    I always enjoy reading one of my favorite authors.

    I bought some GILD, AMGN and CELG this morning.


    I like the 50%+ growth in EPS that I think will occur in about a month. Over the next 6mo - 1 yr I believe an acquisition and a defined HBV strategy will emerge raising the PE.


    Really has become my top pick with the average analyst price target of $186. I like the improved profit margins, 4 new drugs introduced, new indications, 10% 5 year EPS growth and expectation of a 2.5% forward dividend yield.


    Best potential growth of any large cap biotech. Huge pipeline, investments in 30+ smaller biotech research pipelines and strong growth of Revlimid.
    Sep 28, 2015. 12:33 PM | 7 Likes Like |Link to Comment
  • Gilead: The HCV Market Is Far From Mature [View article]
    My one year view remains that

    - HCV is stable or growing on a EPS basis
    - An HBV solution will come into view and a GILD executive recently stated "we think we know how to get there"
    - An acquisition to diversify revenues will happen
    -HIV will deliver stable growth with TAF regimens

    When you put it all together you get a 15 PE X $12.40 = $186

    Which is about a 92% return on my purchase this morning.
    Sep 28, 2015. 10:58 AM | 13 Likes Like |Link to Comment
  • Buy Gilead Sciences At An Attractive Price [View article]
    I remain long and strong in GILD! Bought more today at $97.
    Sep 28, 2015. 10:40 AM | 8 Likes Like |Link to Comment
  • Conflating Gilead's $1,000 Pill With Turing's $750 Pill [View article]
    Interesting article!

    Lots of scrutiny to come on drug prices for the next year.

    However GILD will deliver a 50%+ increase in EPS in about a month.
    Sep 28, 2015. 09:22 AM | 4 Likes Like |Link to Comment
  • The Risk Of Buying Dividend Growth Stocks Without Looking [View article]
    Interesting article!

    I tend to focus on buying stocks that are growing and have good valuations. If that means I take a little more risk I can raise my cash weighting in the portfolio to adjust.

    Some on my list include JNJ, LMT, VZ all of which I believe will grow over the next 10 years. I have my doubts about some like KO/PEP, PG, MCD that many others recommend profusely.

    I also like AMGN which is growing at 10%+ and trading at a 14 PE on 2015 EPS estimates. Further if you take their 2.2% dividend and recognize that it likely gets increased by 10% within a few months you have a forward 2.42% dividend yield and substantial growth.

    CVS has made some smart acquisitions has a 14.5% 5 year growth rate projected and trades at 19.1 PE on 2015 EPS estimates.
    Sep 26, 2015. 09:44 AM | 4 Likes Like |Link to Comment
  • Investing In The World's Greatest Killer Gives Amgen Enormous Upside Potential [View article]
    I will add a few comments regarding AMGN which I feel is the best investment in biotech at this moment and one of the best investments in the S&P500.

    - 14.7 PE on 2015 EPS est
    - 10%+ growth projected for 5 years
    - 4 new drugs this year launched
    - Repatha has the potential to be a huge HR (CVS estimates $100 bil sales PCSK9)
    - AMGN continuing to cut costs and reduce overhead raising profit level
    - Older drugs doing better than expected
    - 14.5 PE based on my 2015 est of $9.90
    - 2.2% dividend likely to get significant bump (est 10%)
    - share price getting hit by IBB/ETF selling rather than on AMGN's merits
    Sep 25, 2015. 11:22 AM | 6 Likes Like |Link to Comment
  • For Long-Term Growth, Look No Further Than Gilead Sciences [View article]
    If anyone else wants to write an article on GILD plenty of new ground remains to be plowed.

    1) effect of pan genotype HCV drug on GILD
    2) Where HBV is in a competitive analysis
    3) Where NASH is in a competitive analysis
    4) HIV status including the potential for a cure and the timing
    5) Presenting a vision of GILD in 2020 from what we know today

    I think the "GILD stock is undervalued and has a low PE" thesis is covered.
    Sep 25, 2015. 11:04 AM | 8 Likes Like |Link to Comment